BioSpecifics Technologies Corp. is a biopharmaceutical company
that has developed and licensed injectable collagenase
for three clinical indications. We have a development
and licensing agreement with Auxilium Pharmaceuticals
www.auxilium.com (Nasdaq
GM: AUXL) for clinical indications in Dupuytren’s
disease, Peyronie’s disease and frozen shoulder (adhesive
capsulitis).
Prior to March 2006, our primary focus was on the manufacture of the FDA licensed product collagenase ointment for use in debridement of dermal ulcers and severely burned areas. Following the sale of our collagenase topical business to DFB BioTech, we reorganized and concentrated all activities on the future development and commercialization of our injectable collagenase products.
|
Stock
Quote
